Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCH | P24723 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258036 | 1.00 | LPAR5 (0.74) | LPAR5USP2HTTP2RY10LPAR1 | |
| SCHEMBL258056 | 1.00 | LPAR5 (0.74) | LPAR5USP2HTTP2RY10LPAR1 | |
| SCHEMBL258063 | 1.00 | LPAR5 (0.74) | LPAR5USP2HTTP2RY10LPAR1 | |
| SCHEMBL258048 | 1.00 | LPAR5 (0.74) | LPAR5USP2HTTP2RY10LPAR1 | |
| SCHEMBL27602487 | 0.98 | LPAR5 (0.72) | LPAR5USP2HTTP2RY10LPAR1 | |
| SCHEMBL27642051 | 0.98 | LPAR5 (0.71) | LPAR5USP2HTTP2RY10LPAR1 | |
| Glycerin SCHEMBL28236478 | 0.94 | LPAR5 (0.67) | LPAR5USP2HTTP2RY10LPAR1 | |
| Glycerin SCHEMBL28048895 | 0.92 | LPAR5 (0.64) | LPAR5USP2HTTP2RY10LPAR1 | |
| SCHEMBL258119 | 0.92 | P2RY10 (0.64) | LPAR5USP2HTTP2RY10LPAR1 | |
| Potassium Ion SCHEMBL1811179 | 0.90 | LPAR5 (0.62) | LPAR5USP2HTTP2RY10LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244984-A1 | Ceramide Production Promoter | KAO CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8440645-B2 | Ceramide production promoter | KAO CORPORATION (JP) | 2013-05-14 | — | — | US | disclosed |
| CN-102438629-A | Ceramide production promoter | KAO CORP | 2012-05-02 | — | — | CN | disclosed |
| US-7968607-B2 | Cosmetics 1-isostearylglycerol-3-Sulfate Sodium Salt, used for constriction of keratinocytes; aging resistance | KOA CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20110105439-A1 | Ceramide Production Promoter | KAO CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-1325737-B1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORP (JP) | 2009-12-16 | — | — | EP | disclosed |
| CN-100494205-C | Phosphorylated glyceryl ether aluminium salts | KAO CORP (JP) | 2009-06-03 | — | — | CN | disclosed |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| CN-1626538-A | Phosphorylated glyceryl ether aluminium salts | KAO CORP (JP) | 2005-06-15 | — | — | CN | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105439-A1 | Ceramide Production Promoter | CERS2, SPTLC1, SGMS1 | LPAR5 1170/4885USP2 4085/4885HTT 4728/4885 |
| US-20130244984-A1 | Ceramide Production Promoter | CERS2, SPTLC1, SGMS1 | LPAR5 1170/4885USP2 4085/4885HTT 4728/4885 |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | LPAR5 115/4885USP2 2585/4885HTT 4782/4885 |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | DSG1, CUTA, OGA | LPAR5 265/4885USP2 2626/4885HTT 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.